🇬🇧 Professor Johann Sebastian de Bono, MB, ChB, FRCP, MSc, PhD, FMedSci

Distinguished Investigators

🇺🇸 United States

Andrei Iagaru, MD Andrew Armstrong, MD Daniel P. Petrylak, MD Geoffrey Johnson, MD Ghassan El-Haddad, MD Jeff Michalski, MD Jeremie Calais, MD, PhD Luke T. Nordquist, MD Michael Gorin, MD Michael J. Morris, MD, PhD Neal Shore, MD Neeraj Agarwal, MD Oliver Sartor, MD Scott Tagawa, MD

🇫🇷 France

Karim Fizazi, MD, PhD

🇨🇦 Canada

Kim Chi, MD

🇬🇧 United Kingdom

Professor Johann Sebastian de Bono, MB, ChB, FRCP, MSc, PhD, FMedSci

🇩🇪 Germany

Professor Ken Herrmann, MD

🇦🇺 Australia

Professor Louise Emmett, MBChB, FRACP, FAANMS, MD

Professor Johann Sebastian de Bono, MB, ChB, FRCP, MSc, PhD, FMedSci

Professor Johann de Bono is Regius Professor of Cancer Research at The Institute of Cancer Research and honorary consultant in medical oncology at The Royal Marsden Hospital. He led on the development of abiraterone, cabazitaxel, enzalutamide, olaparib, lutetium PSMA and the molecular genomic stratification and germline sequencing of advanced prostate cancer. Professor de Bono leads the Drug Development Unit at the Royal Marsden which comprises >100 staff and conducts >50 Phase I clinical trials at any one time and runs a research laboratory. He has been involved in developing more than 200 new agents and is currently evaluating many new drugs in early clinical trials. He has published >600 papers and has mentored many PhD students.